MBX Biosciences Shuffles Leadership as Shares Slide

Hoerter is no stranger to the company’s internal operations, having served as executive chairman since November 2025 following his appointment to the board earlier that year. His track record includes guiding Deciphera Pharmaceuticals through its evolution into a commercial entity, a tenure that concluded with the company's 2024 acquisition by Ono Pharmaceutical. Alongside the CEO change, the board promoted John Smither to chief financial officer, removing the interim tag from his title.

The new leadership faces a demanding schedule. Hoerter confirmed the company remains focused on three primary objectives for the latter half of 2026: launching a Phase 3 trial for the chronic hypoparathyroidism treatment canvuparatide, selecting a triple agonist candidate for obesity, and releasing 12-week data for the experimental drug MBX 4291. Despite these prospects, investors reacted sharply to the news, sending shares down 11.69% to $53.02 in post-market trading. This pullback follows a period of intense growth, with the stock having climbed 83% over the previous three months.